Alkermes Remains Committed to Oncology Innovation
News release
by
Alkermes
Northampton, MA | June 21, 2022 12:15 PM Eastern Daylight Time
On the heels of ASCO22, we remain committed to innovating in the oncology space, particularly for cancers with high unmet needs, like platinum-resistant ovarian cancer. Thomas Herzog, M.D. and Craig Hopkinson M.D. share their insights on how our actively recruiting ARTISTRY-7 clinical trial in platinum-resistant ovarian cancer aspires to address these needs: https://bit.ly/3azbAjw
View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com